Cencora, Inc. $COR Shares Acquired by Schroder Investment Management Group

Schroder Investment Management Group increased its stake in shares of Cencora, Inc. (NYSE:COR) by 2.2% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 285,002 shares of the company’s stock after buying an additional 6,119 shares during the quarter. Schroder Investment Management Group owned about 0.15% of Cencora worth $89,072,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its stake in Cencora by 4.1% in the third quarter. Vanguard Group Inc. now owns 23,395,547 shares of the company’s stock valued at $7,311,810,000 after buying an additional 916,506 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Cencora by 6.3% during the second quarter. Geode Capital Management LLC now owns 4,787,609 shares of the company’s stock worth $1,429,772,000 after acquiring an additional 284,229 shares during the last quarter. JPMorgan Chase & Co. grew its position in shares of Cencora by 21.3% during the third quarter. JPMorgan Chase & Co. now owns 4,677,797 shares of the company’s stock worth $1,461,965,000 after acquiring an additional 821,098 shares during the last quarter. Norges Bank acquired a new stake in shares of Cencora in the 2nd quarter worth about $695,215,000. Finally, Viking Global Investors LP increased its holdings in shares of Cencora by 95.0% in the 2nd quarter. Viking Global Investors LP now owns 2,081,732 shares of the company’s stock worth $624,207,000 after acquiring an additional 1,013,913 shares during the period. 97.52% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Cencora

In related news, EVP Elizabeth S. Campbell sold 3,351 shares of Cencora stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $342.10, for a total value of $1,146,377.10. Following the transaction, the executive vice president owned 23,891 shares of the company’s stock, valued at approximately $8,173,111.10. This trade represents a 12.30% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Silvana Battaglia sold 1,677 shares of the business’s stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $345.00, for a total value of $578,565.00. Following the sale, the executive vice president owned 18,796 shares in the company, valued at approximately $6,484,620. The trade was a 8.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 15,220 shares of company stock valued at $5,282,867 over the last three months. Company insiders own 0.38% of the company’s stock.

Analyst Ratings Changes

Several analysts recently weighed in on COR shares. Barclays lifted their price objective on shares of Cencora from $400.00 to $425.00 and gave the company an “overweight” rating in a research report on Friday, February 13th. Weiss Ratings upgraded shares of Cencora from a “hold (c+)” rating to a “buy (b)” rating in a research note on Thursday, February 5th. Evercore cut their price target on Cencora from $440.00 to $420.00 and set an “outperform” rating on the stock in a report on Thursday, February 5th. Jefferies Financial Group upgraded Cencora from an “underperform” rating to a “buy” rating in a research report on Thursday, January 22nd. Finally, JPMorgan Chase & Co. increased their price objective on Cencora from $417.00 to $419.00 and gave the stock an “overweight” rating in a report on Tuesday, February 10th. Eleven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $399.00.

Cencora Trading Up 0.9%

Shares of NYSE:COR opened at $361.80 on Tuesday. The company has a debt-to-equity ratio of 3.62, a quick ratio of 0.51 and a current ratio of 0.92. The stock has a market capitalization of $70.38 billion, a price-to-earnings ratio of 43.49, a PEG ratio of 1.67 and a beta of 0.68. Cencora, Inc. has a 1-year low of $251.94 and a 1-year high of $377.54. The company has a 50 day moving average price of $354.60 and a 200 day moving average price of $337.09.

Cencora (NYSE:COR) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $4.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.04 by $0.04. Cencora had a return on equity of 176.54% and a net margin of 0.50%.The company had revenue of $85.93 billion for the quarter, compared to analysts’ expectations of $86.12 billion. During the same quarter in the prior year, the company earned $3.73 earnings per share. The firm’s revenue was up 5.5% on a year-over-year basis. On average, research analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, March 2nd. Stockholders of record on Friday, February 13th were given a dividend of $0.60 per share. The ex-dividend date of this dividend was Friday, February 13th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.7%. Cencora’s payout ratio is 28.85%.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.